Henry RodriguezPhD, MBA
Dr. Rodriguez serves as the Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute, National Institutes of Health, where he oversees research decisions, development, and global oncology programs in proteomics. Rodriguez is a recognized leader in cancer research, FDA regulatory affairs, government policy, and business management. He serves on various committees to develop agreements across Federal agencies, and to build public-private partnerships. In addition, Rodriguez is responsible for providing authoritative leadership including policy development on innovative technology initiatives that address NCI's expanding role in biomedical research (proteogenomics).
Rodriguez has received numerous domestic and international awards and honors, including the Diversity Program Alumni Recognition from the Minority Biomedical Research Support program of National Institute of General Medical Sciences; Young Scientific Investigator Award from the Sigma Xi Scientific Research Society; Leveraging Collaboration Award from the FDA; Service Award from the American Association for Clinical Chemistry; Distinguished Alumni Member of the Epsilon of Florida Chapter of Phi Beta Kappa at Florida International University, Distinguished Alumni Torch Award from Florida International University, and Dr. Herbert Wertheim Global Medical Leadership Award from the Florida International University Herbert Wertheim College of Medicine.
He has authored over 90 scientific papers in peer-reviewed journals, including co-edited a best-selling book entitled "Oxidative Stress and Aging: Advances in Basic Science, Diagnostics and Intervention." Rodriguez holds a B.S. in biology/chemistry and a M.S. in toxicology from Florida International University, a Ph.D. in cell and molecular biology from Boston University, and a M.B.A. in finance and management from Johns Hopkins University School of Business.